metformin has been researched along with atorvastatin in 62 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (14.52) | 29.6817 |
| 2010's | 40 (64.52) | 24.3611 |
| 2020's | 13 (20.97) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Taldone, T; Talele, TT; Zito, SW | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Currier, JS | 1 |
| Abourjaily, HM; Alsheikh-Ali, AA; Karas, RH | 1 |
| Moreno Sánchez, D | 1 |
| Athyros, VG; Elisaf, M; Mikhailidis, DP | 1 |
| Lynch, T | 1 |
| Balasubramanian, R; Baliga, VP; Bolmall, C; Kathale, A; Nagraj, LM; Nayak, UP; Periyandavar, I; Sharma, A; Varadharajan, S | 1 |
| Aksakal, O; Gungor, T; Kelekci, S; Mollamahmutoglu, L; Sirvan, L; Soysal, S; Sut, N; Yilmaz, B | 1 |
| Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T | 1 |
| Antoniades, C; Charakida, M; Kamboli, AM; Koniari, K; Marinou, K; Miliou, A; Nikolopoulou, A; Noutsou, M; Papageorgiou, N; Siasos, G; Stefanadi, E; Stefanadis, C; Tousoulis, D | 1 |
| Antoniades, C; Koniari, K; Marinou, K; Miliou, A; Nikolopoulou, A; Noutsou, M; Papageorgiou, N; Stefanadi, E; Stefanadis, C; Tousoulis, D | 1 |
| Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R | 1 |
| Arora, R; Dey, S; Kandhwal, K; Monif, T; Nazarudheen, S; Rao, S; Reyar, S; Singh, MK; Thudi, NR | 1 |
| Awasthi, S; Nagaprashantha, L; Singhal, J; Singhal, SS; Vatsyayan, R | 1 |
| Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Smith, KA | 1 |
| Hart, RJ; Hunter, T; Raval, AD; Stuckey, B | 1 |
| Balk, B; Bujok, K; Fromm, MF; Glaeser, H; Mandery, K; Schmidt, I | 1 |
| Atkin, SL; Coady, AM; Kilpatrick, ES; Sathyapalan, T; Shepherd, J | 1 |
| Li, L; Nouraldeen, A; Wilson, AG | 1 |
| Ceng, C; Han, W; Huang, C; Liu, Y; Zhan, H; Zheng, D | 1 |
| Chung, YM; Han, S; Kim, BH; Lee, H; Lee, HG; Park, CH; Shin, K; Ye, SK | 1 |
| Kumar, V; Singh, A; Singh, BK | 1 |
| Gilowski, W; Krysiak, R; Okopien, B; Szkrobka, W | 1 |
| Fromm, MF; Glaeser, H; Hoier, E; Knop, J; König, J; Misaka, S; Müller, F; Singer, K | 1 |
| Eun Lee, J; Han, S; Hye Park, C; Jeon, EK; Jeong Kim, Y; Kim, DH; Lee, YJ; Oh, JH; Oh, TO; Shin, K | 1 |
| Ambery, P; Atkinson, G; Baylor Curtis, L; Dott, C; Haque, N; LaCroix, K; Min, KW; Stylianou, A | 1 |
| Abou Rayia, DM; Ashour, DS; El-Ebiary, AA; Othman, AA; Saied, EM; Zineldeen, DH | 1 |
| Gillen, M; Kerr, B; Shen, Z; Wallach, K; Yeh, LT; Zhu, N | 1 |
| Alizadeh, A; Kashi, Z; Kianmehr, A; Mahrooz, A | 1 |
| Hao, Z; Li, G; Liao, H; Liu, Y; Xiao, C; Zheng, D | 1 |
| Akhtar, S; Desai, A; Goldwater, R; Han, D; Howieson, C; Kowalski, D; Lademacher, C; Lasseter, KC; Rammelsberg, D; Townsend, R; Yamazaki, T | 1 |
| Brereton, I; Chambers, SK; Chow, CW; Coughlin, GD; Doi, SA; Dunglison, NT; Esler, RC; Gardiner, RA; Gianduzzo, TR; Kienzle, N; Lavin, MF; Lu, M; Medcraft, RJ; Oyama, C; Payton, D; Perry-Keene, J; Richards, RS; Roberts, MJ; Samaratunga, H; Schirra, HJ; Yaxley, JW | 1 |
| Lee, YJ; Oh, JH; Shin, E; Shin, N | 1 |
| Anderson, TW; Derving Karsbøl, J; Golor, G; Hausner, H; Holst, AG; Jacobsen, JB; Wagner, FD | 1 |
| Boros, LG; Collins, TQ; D'Agostino, DP; Hitendra, P; Meuillet, EJ; Somlyai, G | 1 |
| Fang, ZF; Guo, Y; Li, XP; Long, JK; Luo, F; Peng, DQ; Ruan, GY; Xia, Q; Zhao, SP; Zheng, XL | 1 |
| Du, ZY; Farischon, C; Goodin, S; He, Y; Huang, HR; Kim, S; Li, DL; Wang, ZS; Zhang, K; Zhang, LY; Zheng, X | 1 |
| Chen, L; He, M; Lai, B; Li, Z; Shyy, JY; Wang, Y; Yang, Y; Zhang, J | 1 |
| Gemski, C; Guan, E; Li, AP; Liao, M; Ma, B; Xia, CQ; Xiao, G; Zhu, A; Zhu, Q | 1 |
| Fang, H; Hu, J; Li, M | 1 |
| Gu, YY; Guan, QB; Jing, F; Yang, S; Yu, CX | 1 |
| Mohebbati, R; Niazmand, S; Paseban, M; Sahebkar, A; Sathyapalan, T | 1 |
| Amiresmaili, M; Emrani, Z | 2 |
| Dulak, J; Florczyk-Soluch, U; Frołow, M; Józkowicz, A; Kachamakova-Trojanowska, N; Klóska, D; Markiewicz, J; Niżankowski, R; Nowak, WN; Stępniewski, J; Taha, H; Walter, Z | 1 |
| Hassanabad, AF | 1 |
| Glick, A; Johnson, C; Sista, V | 1 |
| Iqbal, R; Qureshi, OS; Raza, SA; Saleem, U; Sarwar, HS; Shahnaz, G; Sohail, MF; Yousaf, AM | 1 |
| Mohamad, A; Zahran, F; Zein, N | 1 |
| Mazumder, N; Parikh, ND; Tapper, EB; Zhao, Z | 1 |
| Ankathi, SK; Banavali, SD; Bhargava, PG; Daddi, A; Goel, M; Gota, V; Jadhav, S; Mandavkar, S; Nashikkar, C; Naughane, D; Ostwal, V; Patkar, S; Ramaswamy, A; Shetty, N; Shriyan, B; Srinivas, S | 1 |
| Coskun, G; Efendic, F; Erdem, E; Hayretdag, C; Irkorucu, O; Keles, P; Kuras, S; Pence, HH; Polat, S; Saker, D; Sapmaz, E; Sapmaz, T; Sevgin, K; Tekayev, M; Topkaraoglu, S | 1 |
| Kowalcze, K; Krysiak, R; Okopień, B | 1 |
| Anghel, R; Forsea, L; Gales, L; Georgescu, M; Mitrea, D; Mitrica, R; Serbanescu, L; Stanculescu, I; Stefanica, I; Trifanescu, O | 1 |
| Chen, M; Li, M; Liu, S; Ma, F; Su, B; Wang, C; Yuan, L; Zhang, S; Zhang, Y; Zheng, Q | 1 |
| Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG | 1 |
| Augusto, CT; de la Paz Scribano Parada, M; Del Carmen Baez, M; Fonseca, I; Rossi, MM; Signorini, F | 1 |
| Hao, SL; Meng, XY; Zhang, CL | 1 |
7 review(s) available for metformin and atorvastatin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
Statins for women with polycystic ovary syndrome not actively trying to conceive.
Topics: Adult; Atorvastatin; Female; Heptanoic Acids; Hirsutism; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperandrogenism; Hypoglycemic Agents; Menstruation Disturbances; Metformin; Polycystic Ovary Syndrome; Pyrroles; Randomized Controlled Trials as Topic; Simvastatin; Young Adult | 2011 |
Structural homologies between phenformin, lipitor and gleevec aim the same metabolic oncotarget in leukemia and melanoma.
Topics: Atorvastatin; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Melanoma; Metformin; Phenformin | 2017 |
The Effect of Statins on Levels of Dehydroepiandrosterone (DHEA) in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis.
Topics: Adult; Atorvastatin; China; Dehydroepiandrosterone; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Middle Aged; Polycystic Ovary Syndrome; Simvastatin | 2019 |
Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy.
Topics: Adenosine Monophosphate; Adrenergic beta-Antagonists; Anthelmintics; Anti-Bacterial Agents; Antihypertensive Agents; Antimalarials; Antineoplastic Agents; Atorvastatin; Breast Neoplasms; Cholesterol; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Mebendazole; Metformin; Mevalonic Acid; Propranolol; Protein Kinases; Proto-Oncogene Proteins B-raf; Receptors, Adrenergic, beta-2; Tyrosine | 2022 |
Comparison of different drug for reducing testosterone levels in women with polycystic ovary syndrome: A systematic review and network meta-analysis.
Topics: Atorvastatin; Female; Humans; Metformin; Network Meta-Analysis; Polycystic Ovary Syndrome; Simvastatin; Spironolactone; Testosterone | 2023 |
14 trial(s) available for metformin and atorvastatin
| Article | Year |
|---|---|
Inflammatory markers and the metabolic syndrome.
Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome | 2005 |
Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Dyslipidemias; Female; Glycemic Index; Heptanoic Acids; Humans; Hypoglycemic Agents; India; Male; Metformin; Middle Aged; Pyrroles | 2008 |
Atorvastatin pretreatment augments the effect of metformin in patients with polycystic ovary syndrome (PCOS).
Topics: Adult; Atorvastatin; C-Reactive Protein; Drug Synergism; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Metformin; Polycystic Ovary Syndrome; Pyrroles; Testosterone | 2010 |
Combined effects of atorvastatin and metformin on glucose-induced variations of inflammatory process in patients with diabetes mellitus.
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hypoglycemic Agents; Inflammation; Male; Metformin; Middle Aged; Pyrroles; Treatment Outcome; Tumor Necrosis Factor-alpha | 2011 |
Impact of 6 weeks of treatment with low-dose metformin and atorvastatin on glucose-induced changes of endothelial function in adults with newly diagnosed type 2 diabetes mellitus: A single-blind study.
Topics: Atherosclerosis; Atorvastatin; Blood Flow Velocity; Blood Glucose; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Lipids; Male; Metformin; Middle Aged; Plethysmography; Pyrroles; Single-Blind Method; Treatment Outcome; Vasodilation | 2010 |
Pharmacokinetics of a fixed-dose combination of atorvastatin and metformin extended release versus concurrent administration of individual formulations: a randomized, open-label, two-treatment, two-period, two-sequence, single-dose, crossover, bioequivale
Topics: Adult; Asian People; Atorvastatin; Cross-Over Studies; Diabetes Mellitus, Type 2; Drug Combinations; Electrocardiography; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrroles; Therapeutic Equivalency; Vital Signs; Young Adult | 2011 |
Atorvastatin therapy decreases androstenedione and dehydroepiandrosterone sulphate concentrations in patients with polycystic ovary syndrome: randomized controlled study.
Topics: Adrenal Glands; Adult; Androstenedione; Atorvastatin; Dehydroepiandrosterone; Dehydroepiandrosterone Sulfate; Double-Blind Method; Female; Heptanoic Acids; Humans; Hyperandrogenism; Insulin; Metformin; Ovary; Placebos; Polycystic Ovary Syndrome; Pyrroles; Testosterone; Treatment Outcome; United Kingdom | 2012 |
Atorvastatin reduces malondialdehyde concentrations in patients with polycystic ovary syndrome.
Topics: Adult; Atorvastatin; Double-Blind Method; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Malondialdehyde; Metformin; Oxidative Stress; Polycystic Ovary Syndrome; Pyrroles; Treatment Outcome | 2012 |
The Effect of Atorvastatin on Cardiometabolic Risk Factors in Bromocriptine-Treated Premenopausal Women with Isolated Hypercholesterolemia.
Topics: Adult; Atorvastatin; Bromocriptine; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet; Dopamine Agonists; Exercise; Female; Fibrinogen; Homocysteine; Humans; Hypercholesterolemia; Hyperprolactinemia; Hypoglycemic Agents; Hypolipidemic Agents; Metformin; Middle Aged; Premenopause; Risk Factors; Uric Acid | 2015 |
Open-label randomized non-inferiority trial of a fixed-dose combination of glimepiride and atorvastatin for the treatment of people whose Type 2 diabetes is uncontrolled on metformin.
Topics: Aged; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Combinations; Drug Therapy, Combination; Equivalence Trials as Topic; Female; Glycated Hemoglobin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Sulfonylurea Compounds | 2016 |
Pharmacokinetic Interactions Between Isavuconazole and the Drug Transporter Substrates Atorvastatin, Digoxin, Metformin, and Methotrexate in Healthy Subjects.
Topics: Adult; Area Under Curve; Atorvastatin; Digoxin; Female; Healthy Volunteers; Humans; Male; Membrane Transport Proteins; Metformin; Methotrexate; Middle Aged; Nitriles; Pyridines; Triazoles; Young Adult | 2017 |
Can atorvastatin with metformin change the natural history of prostate cancer as characterized by molecular, metabolomic, imaging and pathological variables? A randomized controlled trial protocol.
Topics: Antigens, Neoplasm; Atorvastatin; Biomarkers, Tumor; Citric Acid; Double-Blind Method; Drug Therapy, Combination; Humans; Male; Metformin; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Research Design | 2016 |
Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects.
Topics: Adolescent; Adult; Atorvastatin; Cross-Over Studies; Digoxin; Drug Interactions; Drug Therapy, Combination; Female; Glucagon-Like Peptides; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Warfarin; Young Adult | 2017 |
Phase I Study Evaluating Dose De-escalation of Sorafenib with Metformin and Atorvastatin in Hepatocellular Carcinoma (SMASH).
Topics: Antineoplastic Agents; Atorvastatin; Carcinoma, Hepatocellular; Humans; Liver Neoplasms; Metformin; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome | 2022 |
41 other study(ies) available for metformin and atorvastatin
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Inhibition of dipeptidyl peptidase-IV (DPP-IV) by atorvastatin.
Topics: Atorvastatin; Catalytic Domain; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Heptanoic Acids; Hydrogen Bonding; Hydrolysis; Models, Molecular; Protease Inhibitors; Pyrroles | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
How to manage metabolic complications of HIV therapy: what to do while we wait for answers.
Topics: Anabolic Agents; Anti-HIV Agents; Anticholesteremic Agents; Atorvastatin; Exercise Therapy; Gemfibrozil; Growth Hormone; Guidelines as Topic; Heptanoic Acids; HIV Infections; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipodystrophy; Metabolic Diseases; Metformin; Nucleosides; Protease Inhibitors; Pyrroles; Reverse Transcriptase Inhibitors; Risk Factors; Thiazoles; Thiazolidinediones | 2000 |
Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose).
Topics: Acarbose; Adverse Drug Reaction Reporting Systems; Anticholesteremic Agents; Atorvastatin; Chromans; Drug Interactions; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Male; Metformin; Middle Aged; Pyrroles; Simvastatin; Sulfonylurea Compounds; Thiazoles; Thiazolidinediones; Troglitazone | 2002 |
Medication costs as a primary cause of nonadherence in the elderly.
Topics: Aged; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Coronary Disease; Costs and Cost Analysis; Diabetes Mellitus, Type 2; Drug Prescriptions; Drugs, Generic; Female; Heptanoic Acids; Humans; Hyperlipidemias; Hypertension; Hypoglycemic Agents; Metformin; Metoprolol; Patient Compliance; Pharmacists; Pyrroles; Self Administration | 2006 |
Metformin and atorvastatin reduce adhesion formation in a rat uterine horn model.
Topics: Animals; Atorvastatin; Female; Heptanoic Acids; Metformin; Pyrroles; Rats; Rats, Wistar; Tissue Adhesions; Uterus | 2009 |
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha | 2011 |
RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.
Topics: Animals; Antisense Elements (Genetics); Atorvastatin; Gemfibrozil; GTPase-Activating Proteins; Heptanoic Acids; Hypoglycemic Agents; Hypolipidemic Agents; Metabolic Syndrome; Metformin; Mice; Mice, Knockout; Pyrroles; Rosiglitazone; Thiazolidinediones | 2011 |
Inhibition of hepatic uptake transporters by flavonoids.
Topics: 1-Methyl-4-phenylpyridinium; Apigenin; Atorvastatin; Biological Transport; Flavanones; Flavonoids; Food-Drug Interactions; HEK293 Cells; Hepatocytes; Heptanoic Acids; Humans; Inhibitory Concentration 50; Kaempferols; Liver-Specific Organic Anion Transporter 1; Metformin; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transporter 1; Pyrroles; Quercetin; Rutin; Solute Carrier Organic Anion Transporter Family Member 1B3; Sulfobromophthalein; Tritium | 2012 |
Evaluation of transporter-mediated hepatic uptake in a non-radioactive high-throughput assay: a study of kinetics, species difference and plasma protein effect.
Topics: Animals; Atorvastatin; Biological Assay; Biological Transport; Blood Proteins; Cells, Cultured; Cryopreservation; Estrone; Female; Hepatocytes; Heptanoic Acids; High-Throughput Screening Assays; Humans; Kinetics; Liver; Male; Metformin; Organic Anion Transporters; Pravastatin; Pyrroles; Radioactivity; Reproducibility of Results; Species Specificity; Time Factors | 2013 |
Metformin enhances nitric oxide production and diminishes Rho kinase activity in rats with hyperlipidemia.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Drug Evaluation, Preclinical; Heptanoic Acids; Hypercholesterolemia; Male; Metformin; Nitric Oxide; Pyrroles; Rats, Sprague-Dawley; rho-Associated Kinases | 2014 |
Metformin enhances the anti-adipogenic effects of atorvastatin via modulation of STAT3 and TGF-β/Smad3 signaling.
Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Atorvastatin; Cell Differentiation; Cell Survival; Cyclin D1; Heptanoic Acids; Homeostasis; Hypoglycemic Agents; Kruppel-Like Transcription Factors; Metformin; Mice; Pyrroles; Signal Transduction; Smad3 Protein; Smad7 Protein; STAT3 Transcription Factor; Transforming Growth Factor beta; Tumor Suppressor Protein p53 | 2015 |
Ameliorative Effect of Adjunct Therapy of Metformin with Atorvastatin on Streptozotocin-induced Diabetes Mellitus in Rats.
Topics: Animals; Antioxidants; Atorvastatin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Glutathione; Hypoglycemic Agents; Insulin; Lipid Peroxidation; Lipids; Lipoproteins, HDL; Male; Metformin; Rats; Rats, Wistar; Streptozocin; Triglycerides | 2016 |
Inhibitory Effects of Green Tea and (-)-Epigallocatechin Gallate on Transport by OATP1B1, OATP1B3, OCT1, OCT2, MATE1, MATE2-K and P-Glycoprotein.
Topics: Atorvastatin; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Caco-2 Cells; Catechin; Cells, Cultured; Digoxin; HEK293 Cells; Hepatocytes; Humans; Liver-Specific Organic Anion Transporter 1; Metformin; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Organic Cation Transport Proteins; Organic Cation Transporter 1; Organic Cation Transporter 2; Solute Carrier Organic Anion Transporter Family Member 1B3; Tea; Tissue Distribution | 2015 |
Designing of the fixed-dose gastroretentive bilayer tablet for sustained release of metformin and immediate release of atorvastatin.
Topics: Animals; Area Under Curve; Atorvastatin; Chemistry, Pharmaceutical; Delayed-Action Preparations; Dogs; Drug Combinations; Drug Liberation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Metformin; Solubility; Tablets | 2016 |
Atorvastatin and metformin administration modulates experimental Trichinella spiralis infection.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cyclooxygenase 2; Host-Parasite Interactions; Immunohistochemistry; Intestine, Small; Larva; Metformin; Mice; Muscle, Skeletal; Oxidation-Reduction; Oxidative Stress; Trichinella spiralis; Trichinellosis; Vascular Endothelial Growth Factor A | 2016 |
In Vitro and In Vivo Interaction Studies Between Lesinurad, a Selective Urate Reabsorption Inhibitor, and Major Liver or Kidney Transporters.
Topics: Adolescent; Adult; Aged; Atorvastatin; Carrier Proteins; Cell Line; Diuretics; Drug Interactions; Furosemide; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Kidney; Liver; Liver-Specific Organic Anion Transporter 1; Male; Metformin; Middle Aged; Thioglycolates; Triazoles; Uric Acid; Uricosuric Agents; Young Adult | 2016 |
The Role of Metformin Response in Lipid Metabolism in Patients with Recent-Onset Type 2 Diabetes: HbA1c Level as a Criterion for Designating Patients as Responders or Nonresponders to Metformin.
Topics: Adult; Atorvastatin; Biological Transport; Blood Glucose; Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug Monitoring; Drug Resistance; Drug Synergism; Drug Therapy, Combination; Dyslipidemias; Female; Gemfibrozil; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Male; Metformin; Middle Aged | 2016 |
Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration.
Topics: Adult; Atorvastatin; Cross-Sectional Studies; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Overweight; rho-Associated Kinases; Treatment Outcome | 2016 |
High-Dose Metformin May Increase the Concentration of Atorvastatin in the Liver by Inhibition of Multidrug Resistance-Associated Protein 2.
Topics: Animals; Atorvastatin; Dogs; Dose-Response Relationship, Drug; Drug Synergism; Liver; Madin Darby Canine Kidney Cells; Male; Metformin; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Rats; Rats, Sprague-Dawley | 2017 |
Combined use of metformin and atorvastatin attenuates atherosclerosis in rabbits fed a high-cholesterol diet.
Topics: Animals; Atherosclerosis; Atorvastatin; Biomarkers; Biopsy; Cholesterol; Diet, High-Fat; Disease Models, Animal; Gene Expression; Immunohistochemistry; Lipid Metabolism; Male; Metformin; Plaque, Atherosclerotic; Rabbits | 2017 |
Mechanistic Study of Inhibitory Effects of Metformin and Atorvastatin in Combination on Prostate Cancer Cells in Vitro and in Vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atorvastatin; Cell Line, Tumor; Extracellular Signal-Regulated MAP Kinases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Inhibitor of Apoptosis Proteins; Male; Metformin; Mice, SCID; NF-kappa B; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Survivin; Tumor Burden; Xenograft Model Antitumor Assays | 2017 |
Atheroprone flow enhances the endothelial-to-mesenchymal transition.
Topics: AMP-Activated Protein Kinases; Animals; Antigens, CD; Atherosclerosis; Atorvastatin; Cadherins; Cells, Cultured; DNA Methylation; Epigenesis, Genetic; Epithelial-Mesenchymal Transition; Gene Expression Regulation; Human Umbilical Vein Endothelial Cells; Humans; Metformin; Mice, Inbred C57BL; Platelet Endothelial Cell Adhesion Molecule-1; Promoter Regions, Genetic; Pulsatile Flow; Regional Blood Flow; S100 Calcium-Binding Protein A4; Sirtuin 1; Stress, Mechanical; Time Factors; Vimentin; von Willebrand Factor | 2018 |
Comparison of uptake transporter functions in hepatocytes in different species to determine the optimal model for evaluating drug transporter activities in humans.
Topics: Adult; Animals; Atorvastatin; Biological Transport, Active; Catecholamine Plasma Membrane Transport Proteins; Estradiol; Female; Hepatocytes; Humans; Male; Metformin; Middle Aged; Models, Biological; Octamer Transcription Factor-1; Organic Anion Transporters, Sodium-Dependent; Rats; Rats, Sprague-Dawley; Symporters | 2019 |
Apelin‑13 ameliorates metabolic and cardiovascular disorders in a rat model of type 2 diabetes with a high‑fat diet.
Topics: Animals; Atorvastatin; Biomarkers; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Diet, High-Fat; Disease Models, Animal; Energy Metabolism; Heart Function Tests; Hemodynamics; Intercellular Signaling Peptides and Proteins; Lipid Metabolism; Male; Metformin; Oxidation-Reduction; Protective Agents; Rats | 2018 |
Comparison of the Neuroprotective Effects of Aspirin, Atorvastatin, Captopril and Metformin in Diabetes Mellitus.
Topics: Animals; Aspirin; Atorvastatin; Captopril; Diabetes Mellitus, Experimental; Hypoglycemic Agents; Male; Metformin; Neuroprotective Agents; Rats; Rats, Wistar; Streptozocin | 2019 |
Investigating the exposure of Iranian households to catastrophic health expenditure due to the need to purchase medicines.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Atorvastatin; Catastrophic Illness; Cross-Sectional Studies; Drug Costs; Female; Financing, Personal; Health Expenditures; Health Policy; Humans; Iran; Male; Metformin; Middle Aged; Prospective Studies; Surveys and Questionnaires | 2019 |
Studying the impoverishing effects of procuring medicines: a national study.
Topics: Age Factors; Amoxicillin; Anti-Bacterial Agents; Anticholesteremic Agents; Atorvastatin; Female; Health Equity; Health Expenditures; Humans; Hypoglycemic Agents; Iran; Male; Metformin; Models, Statistical; Poverty; Prescription Drugs; Sex Factors; Surveys and Questionnaires | 2019 |
Atorvastatin and Conditioned Media from Atorvastatin-Treated Human Hematopoietic Stem/Progenitor-Derived Cells Show Proangiogenic Activity
Topics: AC133 Antigen; Antigens, CD34; Aspirin; Atorvastatin; Cells, Cultured; Culture Media, Conditioned; Hematopoietic Stem Cells; Heme Oxygenase-1; Humans; Immunoassay; Isothiocyanates; Leukocytes, Mononuclear; Metformin; Neovascularization, Physiologic; Phenotype; Resveratrol; Sulfoxides | 2019 |
Is There a Role for Statins and Metformin in Cancer Therapy?
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Atorvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kallikreins; Male; Metformin; Neoplasms; PC-3 Cells; Prostate-Specific Antigen | 2020 |
Oral Manifestations of Commonly Prescribed Drugs.
Topics: Albuterol; Amlodipine; Anticonvulsants; Antihypertensive Agents; Atorvastatin; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bronchodilator Agents; Deprescriptions; Drug Hypersensitivity; Fluorides; Gingival Overgrowth; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperpigmentation; Hypoglycemic Agents; Lisinopril; Losartan; Metformin; Metoprolol; Mouth Diseases; Omeprazole; Oral Hygiene; Proton Pump Inhibitors; Simvastatin; Thyroxine; Toothpastes; Xerostomia | 2020 |
Enhanced solubility and biopharmaceutical performance of atorvastatin and metformin via electrospun polyvinylpyrrolidone-hyaluronic acid composite nanoparticles.
Topics: Administration, Oral; Animals; Atorvastatin; Biological Availability; Biological Products; Hyaluronic Acid; Metformin; Nanoparticles; Povidone; Rats; Solubility | 2021 |
Bee venom ameliorates cardiac dysfunction in diabetic hyperlipidemic rats.
Topics: Animals; Atorvastatin; Bee Venoms; Diabetes Mellitus, Experimental; Diet, High-Fat; Heart; Hyperlipidemias; Male; Metformin; Rats | 2021 |
Incidence of, Risk Factors for, and Outcomes After Ascites in a Population-Based Cohort of Older Americans.
Topics: Aged; Anticoagulants; Antiviral Agents; Ascites; Atorvastatin; Carvedilol; Diuretics; Fibrosis; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Liver Cirrhosis; Medicare; Metformin; Paracentesis; Rifaximin; Risk Factors; United States | 2022 |
Effects of metformin, letrozole and atorvastatin on inflammation and apoptosis in experimental peritoneal and ovarian endometriosis in the rat.
Topics: Animals; Apoptosis; Atorvastatin; bcl-2-Associated X Protein; Endometriosis; Female; Humans; Inflammation; Interleukin-6; Interleukin-8; Ki-67 Antigen; Letrozole; Metformin; Proto-Oncogene Proteins c-bcl-2; Rats; Tumor Necrosis Factor-alpha | 2022 |
Thyroid Antibody Titers and Hypothalamic-Pituitary-Thyroid Axis Activity in Levothyroxine-Treated Women With Autoimmune Subclinical Hypothyroidism Receiving Atorvastatin or Metformin.
Topics: Atorvastatin; C-Reactive Protein; Female; Hashimoto Disease; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothyroidism; Inflammation; Insulin Resistance; Metformin; Thyroid Hormones; Thyrotropin; Thyroxine | 2022 |
Treatment effect of metformin combined with atorvastatin in reducing in-stent restenosis after percutaneous coronary intervention in coronary artery disease patients with type 2 diabetic patients.
Topics: Atorvastatin; Blood Glucose; Coronary Angiography; Coronary Artery Disease; Coronary Restenosis; Diabetes Mellitus, Type 2; Drug-Eluting Stents; Humans; Metformin; Percutaneous Coronary Intervention; Risk Factors; Sirolimus; Stents; Treatment Outcome | 2022 |
Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing.
Topics: Anti-Obesity Agents; Atorvastatin; Drug Approval; Drug Repositioning; Female; Fructose; Humans; Male; Metformin; Obesity; Phentermine; Pregnancy; Topiramate | 2022 |
Pharmacological Action of Atorvastatin and Metformin on Non-alcoholic Fatty Liver Disease on an Experimental Model of Metabolic Syndrome.
Topics: Animals; Atorvastatin; Liver; Male; Metabolic Syndrome; Metformin; Models, Theoretical; Non-alcoholic Fatty Liver Disease; Rats; Rats, Wistar; Superoxide Dismutase | 2023 |